Drug Trial Radar · NCT02723955
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
829
Actual
Start
Jun 23, 2016
Primary completion
Jul 5, 2023
Study completion Jul 5, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Mar 31, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 93 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or chemotherapy or pembrolizumab plus chemotherapy or dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B expansion phase with pembrolizumab. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
Conditions
- Neoplasms
Interventions
feladilimab (GSK3359609)Drug
GSK3174998Drug
PembrolizumabDrug
DocetaxelDrug
PemetrexedDrug
Paclitaxel plus CarboplatinDrug
Gemcitabine plus CarboplatinDrug
Fluorouracil (5-FU) plus carboplatin or cisplatinDrug
DostarlimabDrug
CobolimabDrug
Bintrafusp alfaDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)Time frame: Up to approximately 367 weeks
- Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 28 days
- Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry ParametersTime frame: Baseline (Day 1) and up to approximately 367 weeks
- Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
- Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology ParametersTime frame: Baseline (Day 1) and up to approximately 367 weeks
- Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
- Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
- Part 1A: Number of Participants With Dose Modifications of FeladilimabTime frame: Up to approximately 367 weeks
- Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)Time frame: Up to approximately 367 weeks
- Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 28 days
- Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry ParametersTime frame: Baseline (Day 1) and up to approximately 367 weeks
- Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
- Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology ParametersTime frame: Baseline (Day 1) and up to approximately 367 weeks
- Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
- Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to BaselineTime frame: Up to approximately 367 weeks
- Part 2A: Number of Participants With Dose Modifications of FeladilimabTime frame: Up to approximately 367 weeks
Locations
28 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Duarte, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Sarasota, Florida
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Shnghai, China
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Villejuif, France
GSK Investigational Site
Siena, Tuscany, Italy
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Amsterdam, Netherlands
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Mága, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.